ReviewFrontiers in medicine2019
Treatment of Infections Due to MDR Gram-Negative Bacteria.
Review in Frontiers in medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 164 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
164 citing papers in PubMed, 2 syntheses or guidelines pooled it, 306 citations in OpenAlex.
- Bibliometric analysis of global research on the clinical applications of aminoglycoside antibiotics: improving efficacy and decreasing risk.Frontiers in microbiology · 2025Pooled it
- Double-carbapenem therapy in the treatment of multidrug resistant Gram-negative bacterial infections: a systematic review and meta-analysis.BMC infectious diseases · 2020Pooled it
- Effective Abatement of Multidrug-resistant Pathogens Employing Natural Polyphenols and Polyphenol-based Formulations: A Systematic Review and Integrated Network Pharmacology Approach.Applied biochemistry and biotechnology · 2026Review
- Extensively drug-resistant ESBL-producing enterobacterales and coexisting antimicrobial resistance genes are associated with mortality in critically ill patients with cancer.Scientific reports · 2026Article
- Microbiological Profile of Pathogens Among Patients at a Tertiary Care Hospital in Mumbai, India.Cureus · 2026Article
- From emerging viral pathogens to pan-resistant bacteria: toward a post-antibiotic era in immunocompromised patients.Annals of medicine and surgery (2012) · 2026Article
- Article
- Systematic Review of Antimicrobial Therapies and Clinical Outcomes inLife (Basel, Switzerland) · 2026Review
- Next-Generation Strategies to Encounter Antimicrobial Resistance (AMR): From Lariocidin to Gene Editing and Nanotechnology-Based Approaches.Molecules (Basel, Switzerland) · 2026Review
- Multidrug-ResistantPolish journal of microbiology · 2026Review
- Article
- Review
- Evaluating the Practical Impact of Fast Microbiology on the Treatment of Bloodstream Infections: Real-World Evidence from a High-Complexity Infectious Disease Center.Antibiotics (Basel, Switzerland) · 2026Article
- Colistin-resistance amongJAC-antimicrobial resistance · 2026Review
- A mechanism-based pharmacokinetic/pharmacodynamic analysis of polymyxin B-based combination therapy against carbapenem-resistantAntimicrobial agents and chemotherapy · 2026Article
- Article
- Clinical outcomes and treatment effectiveness in patients with carbapenem-resistant Enterobacterales infections: a multicenter retrospective cohort study.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2026Article
- Association of biofilm formation with multidrug resistance in burn wound patients isolates ofFrontiers in medicine · 2026Article
- Trends and risk factors of multidrug-resistant hospital-acquired infections in a Tunisian university hospital: repeated point prevalence surveys, 2023-2025.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2026Article
- Duration Matters: Tailoring Antibiotic Therapy for Ventilator-Associated Pneumonia.Antibiotics (Basel, Switzerland) · 2026Review
104 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The treatment of multidrug-resistant Gram-negative bacteria (MDR-GNB) infections in critically ill patients presents many challenges. Since an effective treatment should be administered as soon as possible, resistance to many antimicrobial classes almost invariably reduces the probability of adequate empirical coverage, with possible unfavorable consequences. In this light, readily available patient's medical history and updated information about the local microbiological epidemiology remain critical for defining the baseline risk of MDR-GNB infections and firmly guiding empirical treatment choices, with the aim of avoiding both undertreatment and overtreatment. Rapid diagnostics and efficient laboratory workflows are also of paramount importance both for anticipating diagnosis and for rapidly narrowing the antimicrobial spectrum, with de-escalation purposes and in line with antimicrobial stewardship principles. Carbapenem-resistant Enterobacteriaceae,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.